Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO₃ responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial.

ABSTRACT: NaHCO₃ responsiveness is a novel phenotype where some methicillin-resistant Staphylococcus aureus (MRSA) isolates exhibit significantly lower minimal inhibitory concentrations (MIC) to oxacillin and/or cefazolin in the presence of NaHCO₃. NaHCO₃ responsiveness correlated with treatment response to β-lactams in an endocarditis animal model. We investigated whether treatment of NaHCO₃-responsive strains with β-lactams was associated with faster clearance of bacteremia. The CAMERA2 trial (Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus) randomly assigned participants with MRSA bloodstream infections to standard therapy, or to standard therapy plus an anti-staphylococcal β-lactam (combination therapy). For 117 CA

SUBMITTER: Petersiel N 

PROVIDER: S-EPMC11232399 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature